Power Law company profile

Verdiva Bio

Biotech & Life Sciences · London, United Kingdom · Founded 2025 Unicorn

Oral therapies for obesity and cardiometabolic disorders

Valuation

$1–2.5B

Latest valuation · 2026

Unlock exact value

Headcount

<100

Current team size

Unlock exact value

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

7 investors on Verdiva Bio's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 7 investors entered at this stage

Logos Capital

RA Capital Management

Lilly Asia Ventures

Forbion Capital Partners

OrbiMed

General Atlantic

LYFE Capital

Global footprint

Where Verdiva Bio has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States67.1%

🇬🇧 United Kingdom30.1%

🇳🇱 Netherlands2.8%

3 countries shown

Web traffic by country

5.4K monthly visits
across markets

🇺🇸 United States74.1%

🇬🇧 United Kingdom16.7%

🇮🇳 India5.6%

🇩🇪 Germany5.6%

Top 4 markets shown

Market sentiment

What the market is saying about Verdiva Bio

An AI-synthesized read of the highest-engagement posts about Verdiva Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Verdiva Bio on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles